552 Shares in The Cigna Group (NYSE:CI) Acquired by Windsor Capital Management LLC

Windsor Capital Management LLC bought a new position in The Cigna Group (NYSE:CI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 552 shares of the health services provider’s stock, valued at approximately $200,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Fortitude Family Office LLC purchased a new position in shares of The Cigna Group in the fourth quarter worth approximately $29,000. VisionPoint Advisory Group LLC increased its position in shares of The Cigna Group by 112.2% in the third quarter. VisionPoint Advisory Group LLC now owns 104 shares of the health services provider’s stock worth $30,000 after acquiring an additional 55 shares in the last quarter. Raleigh Capital Management Inc. increased its position in shares of The Cigna Group by 69.5% in the fourth quarter. Raleigh Capital Management Inc. now owns 100 shares of the health services provider’s stock worth $30,000 after acquiring an additional 41 shares in the last quarter. Pineridge Advisors LLC purchased a new position in shares of The Cigna Group in the fourth quarter worth approximately $37,000. Finally, Pacifica Partners Inc. increased its position in shares of The Cigna Group by 73.2% in the fourth quarter. Pacifica Partners Inc. now owns 142 shares of the health services provider’s stock worth $43,000 after acquiring an additional 60 shares in the last quarter. 86.99% of the stock is currently owned by institutional investors.

The Cigna Group Stock Performance

NYSE:CI traded down $1.21 during trading hours on Wednesday, hitting $337.59. 1,491,454 shares of the company traded hands, compared to its average volume of 1,617,163. The stock has a market capitalization of $95.90 billion, a price-to-earnings ratio of 27.72, a P/E/G ratio of 1.03 and a beta of 0.53. The Cigna Group has a twelve month low of $253.95 and a twelve month high of $365.71. The firm has a 50-day moving average of $342.12 and a 200 day moving average of $332.66. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.75.

The Cigna Group (NYSE:CI) last released its earnings results on Thursday, May 2nd. The health services provider reported $6.47 EPS for the quarter, beating the consensus estimate of $6.17 by $0.30. The firm had revenue of $57.25 billion during the quarter, compared to analysts’ expectations of $56.59 billion. The Cigna Group had a net margin of 1.76% and a return on equity of 17.24%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company earned $5.41 EPS. On average, analysts forecast that The Cigna Group will post 28.47 EPS for the current year.

The Cigna Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 20th. Shareholders of record on Tuesday, June 4th were issued a $1.40 dividend. This represents a $5.60 annualized dividend and a yield of 1.66%. The ex-dividend date was Tuesday, June 4th. The Cigna Group’s dividend payout ratio (DPR) is presently 45.98%.

Insider Buying and Selling at The Cigna Group

In other The Cigna Group news, insider Brian C. Evanko sold 4,795 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $345.01, for a total value of $1,654,322.95. Following the sale, the insider now owns 39,923 shares of the company’s stock, valued at approximately $13,773,834.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other The Cigna Group news, insider Brian C. Evanko sold 4,795 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $345.01, for a total value of $1,654,322.95. Following the sale, the insider now owns 39,923 shares of the company’s stock, valued at approximately $13,773,834.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Hoeltzel Mary T. Agoglia sold 5,946 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $348.71, for a total transaction of $2,073,429.66. Following the completion of the sale, the senior vice president now directly owns 2,595 shares in the company, valued at approximately $904,902.45. The disclosure for this sale can be found here. Insiders have sold 22,988 shares of company stock valued at $7,975,726 in the last 90 days. 0.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of The Cigna Group from $432.00 to $435.00 and gave the company an “overweight” rating in a research report on Thursday, May 30th. Barclays assumed coverage on shares of The Cigna Group in a research report on Wednesday, March 6th. They set an “overweight” rating and a $393.00 price objective on the stock. Piper Sandler assumed coverage on shares of The Cigna Group in a research report on Wednesday. They set an “overweight” rating and a $400.00 price objective on the stock. Oppenheimer boosted their price objective on shares of The Cigna Group from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, StockNews.com downgraded shares of The Cigna Group from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 12th. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $376.20.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.